Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

12,5 mg bzw. 25 mg zugelassen. Bei Patienten mit einer moderaten Einschränkung der Nierenfunktion (Creatinin-Clearance [CrCl] > 30 bis < 50 ml/min) beträgt die Dosis Alogliptin einmalig 12,5 mg pro Tag, und bei Patienten mit schwerer Einschränkung der Nierenfunktion (CrCl > 15 bis < 30 ml/min) und solchen mit Nierenerkrankungen im Endstadium (ESRD) (CrCl < 15 ml/min oder mit Hämodialysebedarf) beträgt die Dosis Alogliptin einmalig 6,25 mg pro Tag.

Alogliptin ist in Europa derzeit noch nicht zugelassen. VIPIDIA (Alogliptin), VIPDOMET (Alogliptin und Metformin FDC) sowie INCRESYNC (Alogliptin und Pioglitazon FDC) werden gegenwärtig von der Europäischen Arzneimittel-Agentur (EMA) geprüft und wurden vom Committee for Medicinal Products for Human Use (CHMP) im Juli 2013 positiv bewertet. Alogliptin wurde auch zur Anwendung in China, Mexiko und Südkorea zugelassen, obgleich die Therapie auf diesen Märkten noch nicht erhältlich ist.

Die Wirksamkeit von Alogliptin wurde als Ergänzung zu Diät und Bewegung sowie als Zusatztherapie für andere Antidiabetika untersucht, darunter Metformin, Pioglitazon, Insulin und Sulfonylharnstoffe. In diesen Studien wurde Alogliptin als 25-mg-Tablette einmal täglich eingenommen und zeigte eine klinisch und statistisch signifikante Reduzierung des HbA1c mit einem guten Verträglichkeitsprofil und einer geringen Hypoglykämie-Rate im Vergleich zur aktiven Kontrolle oder Placebo. Studienergebnisse legten nahe, dass Alogliptin bei gemeinsamer Verabreichung mit Metformin oder Pioglitazon in einer jeweiligen Therapie mit freier Dosierung zu einer wesentlichen Verbesserung der Blutzuckerkontrolle führte.

Informationen zu Takeda Pharmaceutical Company Limited
Takeda ist in Osaka, Japan, ansässig und ist ein weltweit agierendes Unternehmen mit Schwerpunkt
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... 2014 Research and Markets has ... Therapeutics Market & Pipeline Insight 2014" report to ... to prevent and eradicate the prevalence of cancer have ... confined to low specificity, safety and large number of ... a better solution. It has been discovered that peptides ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Research and Development Trend Forecast of Pharmaceutical Equipment ... Research and Development Trend Forecast of ... 2014-2018 mainly analyzes China,s pharmaceutical ... supply & demand, competition landscape, and business performance of ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... UBM Live today announced details of the ... pharmaceutical contract services and outsourcing. ICSE, hosted from June ... the most international pharmaceutical events line-up in China, which ... pharma machinery and equipment, BioPh China for the biopharmaceuticals ...
... Stereotaxis, Inc. (NASDAQ: STXS ) today ... 31, 2011.  First quarter results included continued strong momentum ... Odyssey™ systems and growth in recurring revenue.  In addition, ... which enhances the efficiency and versatility of the Niobe ...
Cached Medicine Technology:ICSE China to Offer Inaugural Conference Programme in 2011 2ICSE China to Offer Inaugural Conference Programme in 2011 3Stereotaxis Reports First Quarter 2011 Financial Results 2Stereotaxis Reports First Quarter 2011 Financial Results 3Stereotaxis Reports First Quarter 2011 Financial Results 4Stereotaxis Reports First Quarter 2011 Financial Results 5Stereotaxis Reports First Quarter 2011 Financial Results 6Stereotaxis Reports First Quarter 2011 Financial Results 7
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
(Date:9/1/2014)... NAPW honors ... Orthopedics Pain Treatment & Cardiology, as a ... is recognized with this prestigious distinction for leadership ... organization of women in the country, spanning virtually ... Professional Women is a powerfully vibrant networking community ...
(Date:9/1/2014)... (PRWEB) September 02, 2014 Spine Team ... annual Reader’s Choice ‘Best of 2014’ award based on ... Northeast Tarrant County, Las Colinas & Coppell, Rockwall & ... would like to thank our patients and the residents ... Texas as LIVING magazine’s ‘Best of 2014’ in the ...
(Date:9/1/2014)... an innovative Washington State University study of deadly force ... black people. But when it came time to shoot, ... longer to pull the trigger against them than against ... the recent Journal of Experimental Criminology , grow ... disproportionate number of ethnic and racial minorities shot by ...
(Date:9/1/2014)... UWDress.com, a well-known wedding dress manufacturer and ... green bridesmaid dresses for its new and old ... company’s online category. What’s more, they are offered at ... offer is specially launched to celebrate the coming of ... have won great appreciation from worldwide clients. Now, the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Laura Brinkley, Manager, Gibson Orthopedics Pain Treatment & Cardiology Clinic, a 2014 Professional Woman of the Year 2Health News:Spine Team Texas chosen in LIVING Magazine’s Reader’s Choice Awards 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 3Health News:2014 Lime Green Bridesmaid Dresses Offered At UWDress.com 2
... could help keep ones mind working.The study also found those ... fat have an increased risk of cognitive impairment during middle ... eat could play a role in your risk for dementia. ... with a lower risk of dementia. Researchers in the Netherlands ...
... in the recent issue of British Medical Journal say ... suicides and suicidal attempts.// ,Depression is characterized ... activities, low levels of self-esteem and confidence, and in ... and suicide. ,Clinical depression, also known as ...
... thyroid problem may have a lower risk of developing ... have shown that one of the circulating thyroid hormones ... mammary gland cells responded to thyroid hormones , population ... thyroid hormone and breast cancer. ,In a recent ...
... recent study researchers suggest that women drink wine to keep their ... wine is good for the heart. Although much of the research ... men, it is still not clear why moderate amounts of wine ... effects of wine on women’s hearts, the alcohol habits of 102 ...
... research conducted by Northwestern University about the effects of epidural ... analgesic given at the early stages of labor does not ... in their final term were observed for the study. All ... women who were given epidural in the early stages of ...
... onset wheezing is associated with high levels of allergies, ... the longest duration of wheezing also appear to have ... later in childhood end up with the same characteristics ... involved nearly 1,500 children born on the Isle of ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: